Odaia, a Toronto, Ontario, Canada and Boston, MA-based AI-powered commercial insights SaaS platform for pharmaceutical companies, closed a $13.8m USD Series A funding.
The round was led by Flint Capital with participation from Innospark Ventures, Alumni Ventures, Graphite Ventures and current investors BDC Capital’s Women in Tech Fund, MaRS IAF, StandUp Ventures, Panache Ventures and others. Andrew Gershfeld, who currently serves as Partner at Flint Capital, will advise ODAIA and represent Flint on the ODAIA board of directors. Also joining ODAIA’s board of directors is Matt Fates, Venture Partner at Innospark Ventures.
Funds will be used to enhance platform features and to expand sales, marketing and customer success teams to support market expansion.
Led by Philip Poulidis, co-founder & CEO, Odaia is a SaaS company combining multivariate data analysis, process mining and AI to offer predictive analytics to pharmaceutical and life sciences commercial teams. Many of the world’s largest pharmaceutical companies have leveraged MAPTUAL for actionable commercial insights including Janssen, Novo Nordisk, AstraZeneca, among others.
MAPTUAL consolidates a pharma company’s internal and external data and applies advanced analytics and machine learning to deliver predictive insights in real time to sales and marketing teams, including predictive targeting and sales forecasting, physician segmentation, omni-channel attribution and next-best-engagement, allowing them to deploy resources more efficiently and create personalised customer engagements.
FinSMEs
10/02/2022